FilingReader Intelligence
Zelgen Bio gets clinical trial approval for combination therapy
August 21, 2025 at 09:21 AM UTC•By FilingReader AI
Suzhou Zelgen Biopharmaceuticals received approval from China's National Medical Products Administration for clinical trials of ZG005 for injection, ZGGS18 for injection, and gecasertinib hydrochloride tablets for patients with advanced solid tumors.
The approval is not expected to impact the company's short-term financial performance.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:688266•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Suzhou Zelgen Biopharmaceuticals publishes news
Free account required • Unsubscribe anytime